BioPharmSignal logoBioPharmSignal

Biotech News

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Salarius Pharmaceuticals (SLRX)Salarius PharmaceuticalsConference / presentation

– Live video webcast on Tuesday, February 10 th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today

Related news

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.

Recent company news

SLRXSalarius Pharmaceuticals2026-04-27 12:45 EST

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

SLRXSalarius Pharmaceuticals2026-04-09 12:36 EST

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

SLRXSalarius Pharmaceuticals2026-04-06 13:15 EST

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

SLRXSalarius Pharmaceuticals2026-04-02 13:00 EST

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SLRXSalarius Pharmaceuticals2026-03-11 12:30 EST

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States